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Background. Renal kallikrein excretion is diminished in essen-
tial hypertension, especially in African-Americans, and evidence
exists for a major gene effect on the kallikrein phenotype. In
addition, urinary kallikrein excretion differs by gender, with
ovulating females having greater kallikrein excretion than males
or postmenopausal females. Recent studies have shown that renal
kallikrein excretion varies in females during the ovulatory cycle,
with levels rising during the luteal phase and returning during the
follicular phase to levels that are similar to those of males. In
family studies, gender differences in urinary kallikrein excretion
were present in white subjects, but not black subjects. We
therefore hypothesized dysregulation of kallikrein biosynthetic
responses in African-Americans.
Methods. We determined urinary kallikrein activity [chromo-
genic substrate S2266 (D-val-leu-arg-paranitroanilide) assay; in
mU/mg creatinine] in white (N 5 15) and black (N 5 11) ovulating
females during the ovulatory cycle. Serum progesterone, estrogen,
plasma renin activity as well as urinary aldosterone, and urinary
electrolytes were determined to investigate changes between
mid-follicular and mid-luteal phases in the two groups.
Results. White and black groups were matched for age, body
mass index, blood pressure, heart rate and renal function. Ovula-
tory cycle phases were confirmed by serum progesterone deter-
minations, which increased significantly in whites and blacks to a
comparable degree [0.84 6 0.14 nmol/liter (mid-follicular) to
29.77 6 4.70 nmol/liter (mid-luteal) in whites, 0.67 6 0.08
nmol/liter (mid-follicular) to 28.62 6 5.83 nmol/liter (mid-luteal)
in blacks; P , 0.001 for cycle effect, P 5 NS for race effect and
race X cycle interaction]. Urinary kallikrein activity increased
from 623 6 86 mU/mg creatinine (mid-follicular) to 948 6 142
mU/mg creatinine (mid-luteal) in whites, but did not change in
blacks during the ovulatory cycle [239 6 73 mU/mg creatinine
(mid-follicular] to 244 6 41 mU/mg creatinine (mid-luteal)].
Two-way ANOVA revealed significant effects on urinary kal-
likrein for race (P , 0.001), cycle (P , 0.05), and race X cycle
interaction (P , 0.05). Thus, white females had higher urinary
kallikrein than black females, and demonstrated a significant
increase in urinary kallikrein excretion during the ovulatory cycle,
whereas no significant change in urinary kallikrein activity was
seen in the black group. Enzyme kinetic studies and mixing studies
demonstrated that these racial differences in renal kallikrein
excretion were quantitative, rather than due to qualitative differ-
ences in the renal kallikrein enzyme or due to the presence of a
kallikrein inhibitor.
Conclusions. These results suggest pronounced blunting of
menstrual cycle changes in urinary kallikrein excretion in black
females. Blunted urinary kallikrein responses during the ovulatory
cycle are consistent with dysregulation of renal kallikrein biosyn-
thetic responses in African-Americans, a group at increased risk
for hypertension.
Renal kallikrein is a serine protease that releases kinins
from their natural substrate kininogen [1, 2]. There is
increasing evidence that the renal kallikrein-kinin system
has a role in blood pressure regulation and in the patho-
genesis of hypertension [3]. Several reports indicate that
urinary kallikrein excretion is decreased in essential hyper-
tension in humans and in models of experimental hyper-
tension [4, 5]. Thus, reduced urinary kallikrein may reflect
a deficiency in the endogenous kallikrein/kinin vasodilatory
system that contributes to the pathogenesis of hyperten-
sion. Previous studies demonstrated that urinary kallikrein
excretion is diminished in family members at risk for
hereditary (essential) hypertension [6, 7], and that urinary
kallikrein is one of the major genetic markers associated
with family history of hypertension [7]. Also, evidence for
genetic linkage between the kallikrein locus and blood
pressure has been reported in the rat [8]. Recent studies
suggest that diminished urinary kallikrein excretion is as-
sociated with salt sensitivity of blood pressure [9–11].
Kallikrein excretion is also diminished in African-Ameri-
cans and deficiency of the kallikrein-kinin renal vasodila-
tory system may explain many of the unique features of
essential hypertension in some black subjects [12].
Gender differences in renal kallikrein excretion have
been reported, with females excreting more kallikrein than
males [13]. Albano et al have shown that urinary kallikrein
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excretion varies during the ovulatory cycle, with levels
rising during the luteal phase and returning during the
follicular phase to levels that are similar to those of males
(or post-menopausal females) [14]. However, the effect of
race on the ovulatory cycle changes in urinary kallikrein has
not been examined thus far. Recent family studies revealed
that urinary kallikrein differs by gender; however, gender
difference in urinary kallikrein were largely restricted to
white subjects, and were not seen in black subjects [15].
We therefore hypothesized that there is a dysregulation
of kallikrein biosynthetic responses in African-Americans,
and tested this hypothesis by determining urinary kallikrein
activity during the phases of the ovulatory cycle in white
and black women.
METHODS
Subjects
We studied 26 subjects, 15 white and 11 black females
(age range 22 to 49, mean 38 6 2 years) sequentially over
a duration of four weeks. All subjects were healthy adult
females without evidence of cardiovascular, renal or other
diseases. Subjects were all normotensive (diastolic blood
pressures consistently ,90 mm Hg on 3 separate determi-
nations), ovulating females with regular menstrual cycles
(26 to 30 days). Subjects were on no medications, including
oral contraceptives, and were unrestricted in their diet.
Subjects were stratified by race as Caucasians and Afri-
can-Americans based on self-identification. 15 subjects (8
white and 7 black) had positive family history for hyperten-
sion, and 11 subjects (7 white and 4 black) had negative
family history for hypertension.
All subjects gave written informed consent, and the study
was approved by the Human Subjects Committee at the
University of California, San Diego.
Study design
Each subject reported to the study unit after an overnight
fast on day 0, day 7, day 14 and day 21 (6 2 days) of the
ovulatory cycle, corresponding respectively to menses, mid-
follicular, ovulation, and mid-luteal phases of the cycle. On
each visit, body weight was recorded. Blood pressure and
heart rate were obtained in triplicate with the subject in the
sitting position, using the Dinamap automatic blood pres-
sure device (Critikon Inc., Tampa, FL, USA). Blood sam-
ples were collected at each visit for determination of serum
progesterone and estrogen concentrations, plasma renin
activity, and serum chemistries including creatinine. A spot
urine sample was obtained from each subject at each visit
and frozen at 270° before assay.
Assays
Urine samples were assayed for kallikrein activity using
the chromogenic substrate S2266 (D-val-leu-arg-parani-
troanilide; Chromogenix, Inc.) and values were normalized
by urine creatinine and expressed as mU/mg creatinine [16].
The activity of kallikrein per litre of urine is calculated from
the formula: U/liter 5 9.55 3 A, where A 5 absorbance in
a photometer at 405 nm [16]. Urine aldosterone concen-
trations were determined by radioimmunoassay (Biotecx
Laboratories, Houston, TX, USA); plasma renin activity
was determined by radioimmunoassay (Incstar Corpora-
tion, Stillwater, MN, USA); serum progesterone concen-
trations were determined as previously described [17] and
serum estrogen concentrations (17 b estradiol and estrone)
were determined by radioimmunoassay (Diagnostic Sys-
tems Laboratories, Webster, TX, USA).
Glomerular filtration rate was estimated using the Cock-
croft-Gault algorithm [18]:
~140 2 age!*Wt, kg
72*SCr, mg/dl
The result from this formula was multiplied by 0.85 (cor-
rection factor for females) [18] and normalized for body
surface area.
Statistics
Results are expressed as mean 6 SEM. Subject character-
istics at the mid-follicular time point were analyzed by
unpaired Student’s t-test. Changes in all parameters during
the ovulatory cycle were analyzed by two-factor repeated
measures ANOVA, factoring for the effects of ovulatory
cycle (over time) and race. Multiple regression analysis was
done to simultaneously test the effects of several indepen-
dent variables. Statistical analyses were performed using
SYSTAT statistical computing programs [19] on an IBM
compatible microcomputer.
RESULTS
Subject characteristics
Demographic and hemodynamic characteristics taken at
the mid-follicular phase for the 26 subjects studied are
shown in Table 1. White and black subjects were matched
overall (P . 0.05) for age, weight, body mass index, systolic,
diastolic and mean arterial blood pressures, heart rate,
serum creatinine and renal function (as estimated by
Cockroft-Gault algorithm). White and black subjects were
also matched for urinary sodium excretion, urinary aldo-
sterone concentrations and plasma renin activity (P .
0.05). However, white subjects had significantly higher
urinary potassium excretion rates than black subjects (P 5
0.004).
Figure 1 shows serum progesterone concentrations that
were determined to confirm ovulatory cycle phases in each
subject. There were no significant differences in serum
progesterone concentrations overall, between white and
black subjects (P 5 0.833, for race effect). Serum proges-
terone concentrations increased significantly from mid-
follicular (Day 7) to mid-luteal phases (Day 21) (0.84 6
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0.14 to 29.77 6 4.70 nmol/liter in whites and 0.67 6 0.08 to
28.62 6 5.83 nmol/liter in blacks, P , 0.001 for time effect).
The increases in serum progesterone concentrations from
the mid-follicular to mid-luteal time points were compara-
ble in whites and blacks (P 5 0.868 for race by time
interaction).
Similarly, serum estrogen (17 b estradiol and estrone)
concentrations did not differ between white and black
subjects (both P . 0.05 for race effect); 17 b estradiol and
estrone concentrations increased significantly from mid-
follicular (51.6 6 5.3 and 54.4 6 9.5 pg/ml, respectively, in
whites; 48.1 6 3.3 and 40.6 6 4.9 pg/ml in blacks) to
mid-luteal time point (65.7 6 7.1 and 64.2 6 11.5 pg/ml,
respectively, in whites; 73.7 6 7.8 and 71.4 6 18.2 pg/ml,
respectively, in blacks), and the increases were similar in
the two groups (race by time interactions, P 5 0.423 for 17
b estradiol and P 5 0.289 for estrone).
Results of urinary kallikrein excretion during the ovula-
tory cycle for white and black subjects are shown in Figure
2. Overall, urinary kallikrein excretion was significantly
higher in white subjects compared to black subjects (P ,
0.001 for race effect). In addition, urinary kallikrein activity
increased significantly from mid-follicular (623 6 86
mU/mg creatinine) to mid-luteal (948 6 142 mU/mg creat-
inine) time point in white subjects. By contrast, there was
no change in urinary kallikrein excretion during the ovula-
tory cycle in black females (239 6 73 mU/mg creatinine at
mid-follicular and 244 6 41 mU/mg creatinine at mid-luteal
phase). This racial difference was indicated by a P value of
0.040 for time effect and a P value of 0.047 for race by time
interaction in the two-way repeated measures ANOVA.
Urinary aldosterone excretion tended to be higher in
white subjects compared to black subjects (P 5 0.052 for
race effect). Urinary aldosterone excretion increased sig-
nificantly from mid-follicular (294 6 35 pg/mg creatinine in
Fig. 1. Serum progesterone concentrations in females during the ovula-
tory cycle. The increase in serum progesterone concentration from the
mid-follicular phase (Day 7) to the mid-luteal phase (Day 21) was
comparable in white (E) and black (F) subjects (P 5 0.833 for race effect,
P , 0.001 for time effect, P 5 0.868 for race by time interaction by
two-way ANOVA).
Fig. 2. Renal kallikrein excretion in females during the ovulatory cycle.
Renal kallikrein excretion was significantly greater in white (V) female
subjects compared to black (v) female subjects (P , 0.001 for race effect).
The increase in renal kallikrein excretion from the mid-follicular phase
(Day 7) to the mid-luteal phase (Day 21) phase was observed only in white
subjects; renal kallikrein excretion during the ovulatory cycle remained
unchanged in black subjects (P 5 0.040 for time effect and P 5 0.047 for
race by time interaction by two-way ANOVA).
Table 1. Subject characteristics (mid-follicular phase)
Parameter Whites Blacks P
N 15 11 —
Age, years 39 6 2 36 6 2 0.516
FH (1/2) 8/7 7/4 0.599a
Weight, kgs 70 6 4 77 6 6 0.357
BMI, kg/m2 26 6 1 28 6 2 0.342
SBP, mm Hg 109 6 3 117 6 4 0.098
DBP, mm Hg 65 6 2 67 6 2 0.469
MAP, mm Hg 80 6 2 84 6 2 0.192
HR, beats/min 73 6 3 76 6 4 0.542
SCr, mg/dl 0.65 6 0.02 0.74 6 0.05 0.102
GFR, ml/min/1.73 m2 130 6 6 126 6 11 0.747
UNa1, mmol/mg creatinine 0.117 6 0.016 0.132 6 0.025 0.599
UK1, mmol/mg creatinine 0.072 6 0.009 0.039 6 0.003 0.004
UAldo, pg/mg creatinine 294 6 35 225 6 34 0.182
Plasma renin activity, ng/ml/hr 2.5 6 0.8 3.8 6 1.0 0.324
Abbreviations are: FH, family history of hypertension (positive/nega-
tive); SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP,
mean arterial pressure; HR, heart rate; SCr, serum creatinine; GFR,
glomerular filtration rate estimated using the Cockcroft Gault algorithm;
UNa1, urinary sodium excretion; UK1, urinary potassium excretion; UAldo,
urinary aldosterone concentration.
a P value from Chi-square test
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whites and 225 6 35 pg/mg creatinine in blacks) to mid-
luteal (673 6 109 pg/mg creatinine in whites and 423 6 66
pg/mg creatinine in blacks) phases, as indicated by a P value
of ,0.001 for time effect; this increase was similar in both
the white and black groups, P 5 0.196 for race by time
interaction (Table 2).
Additional hemodynamic and biochemical changes in
white and black subjects during the ovulatory cycle are
shown in Table 2. The changes in weight, mean arterial
pressure and renal function from mid-follicular to mid-
luteal phases, during the ovulatory cycle were similar in
both white and black subjects (P . 0.05 for race by time
interaction in two-way ANOVA). Urinary sodium excre-
tion tended to decrease from mid-follicular (0.117 6 0.016
mmol/mg creatinine in whites and 0.132 6 0.025 mmol/mg
creatinine in blacks) to mid-luteal phase (0.087 6 0.010
mmol/mg creatinine in whites and 0.106 6 0.017 mmol/mg
creatinine in blacks, P 5 0.053 for time effect) in both
whites and blacks (P 5 0.873 for race by time interaction).
White subjects had significantly greater urinary potassium
excretion compared to black subjects (P 5 0.002 for race
effect), with no change in potassium excretion during the
ovulatory cycle for both groups. There was no racial
difference in plasma renin activity (P 5 0.833 for race
effect); however, plasma renin activity increased signifi-
cantly during the ovulatory cycle in both white and black
groups (2.5 6 0.8 ng/ml/hr in whites and 3.8 6 1.0 ng/ml/hr
in blacks at midfollicular phase to 5.4 6 1.1 ng/ml/hr in
whites and 7.3 6 1.7 ng/ml/hr in blacks at mid-luteal phase,
P 5 0.019 for time effect and P 5 0.570 for race by time
interaction in the two-way ANOVA).
To control for the effects of several independent vari-
ables on the changes in kallikrein excretion (dependent
variable), we evaluated these data by multiple regression
analysis, the results for which are shown in Table 3. Of all
the independent variables entered in the model, race was
the only significant unique predictor of urinary kallikrein
activity at mid-luteal phase of the ovulatory cycle. The
combination of variables used in the multiple regression
analysis predicted urinary kallikrein activity with consider-
able power (r 5 0.814, R2 5 0.663, F8,16 5 3.936, P 5 0.009)
To investigate whether the observed racial differences in
renal kallikrein activity were quantitative or due to quali-
tative differences in the renal kallikrein enzyme, we per-
formed enzyme kinetic studies, examining kallikrein en-
zyme/substrate interactions at varying substrate
concentrations in a subgroup of white and black subjects.
Results of these studies are shown in Figure 3 as a double
reciprocal (Lineweaver-Burk) plot of enzyme reaction ve-
locity (y axis) versus substrate concentrations (x axis) in
representative white and black subjects. KM values as
determined from the x intercept did not differ between
these individuals. Grouped data (whites N 5 7, blacks N 5
7) indicated that whereas there was a significant difference
(P , 0.05 by unpaired t-test) in Vmax for renal kallikrein
between white (877 6 228 mU/mg creatinine) and black
(325 6 123 mU/mg creatinine) groups, no significant dif-
ference in Km values were noted (0.45 6 0.2 mM for whites
and 0.40 6 0.19 mM for blacks, P 5 0.840).
To evaluate whether the observed racial differences in
renal kallikrein activity were due to the presence of an
endogenous peptide inhibitor in the urine, we performed
mixing studies, in which kallikrein activity was determined
separately in urine samples from 9 white and 9 black
subjects and in mixed urine samples (urine samples from
white and black subjects randomly paired and mixed 1:1).
There was no significant difference between the enzymatic
activity detected in the mixed samples (207 6 35 mU/mg
creatinine, N 5 9) and the mean enzymatic activity of the
two samples assayed separately (198 6 28 mU/mg creati-
nine, N 5 9 pairs, P 5 0.804).
DISCUSSION
There is extensive evidence for gender effects and racial
differences in the pathogenesis and complications of hyper-
tension [20–27]. Racial differences in the renal kallikrein/
kinin vasodilator system has also been reported [3, 28, 29].
Urinary kallikrein excretion also differs by gender, with
ovulating females excreting greater urinary kallikrein than
males or postmenopausal females. Cyclical variation in
urinary kallikrein excretion in ovulating females during the
ovulatory cycle has been reported previously [14], but the
effect of race on ovulatory cycle changes in urinary kal-
likrein has not been evaluated. In this study, we examined
Table 2. Hemodynamic and biochemical changes in females during the
ovulatory cycle
Parameter Whites Blacks P
D Weight, kgs 0.06 6 0.20 20.27 6 0.29 0.342
D MAP, mm Hg 20.11 6 1.87 20.73 6 2.35 0.837
D GFR, ml/min/1.73 m2 23.36 6 5.35 26.08 6 6.43 0.747
D UNa1, mmol/mg creatinine 20.030 6 0.020 20.026 6 0.017 0.873
D UK1, mmol/mg creatinine 0.006 6 0.017 0.012 6 0.007 0.795
D UAldo, pg/mg creatinine 365 6 101 198 6 58 0.196
D Plasma renin activity, ng/ml/hr 2.2 6 1.5 3.5 6 1.7 0.570
D Ukallikrein, mU/mg creatinine 325 6 120 5 6 67 0.047
Abbreviations are in Table 1.
Table 3. Multiple linear regression with the dependent variable as
urinary kallikrein excretion (mid-luteal phase)
Independent
variables Coefficient
Standardized
coefficient T P
Age 218.950 20.261 21.360 0.193
Weight 29.514 20.291 21.276 0.220
MAP 24.883 0.302 1.286 0.217
GFR 7.358 0.345 1.910 0.074
UNa1 304.264 0.026 0.141 0.890
UK1 2112.079 0.164 0.864 0.400
UAldo 20.268 20.170 20.713 0.486
Race 2770.765 20.697 23.431 0.003
N 5 26. Abbreviations are in Table 1.
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urinary kallikrein activity in normotensive ovulating fe-
males during the phases of the ovulatory cycle and demon-
strated significant increases in urinary kallikrein excretion
during the luteal phase in white females, and absence of
ovulatory cycle changes in renal kallikrein excretion in
black females.
The luteal phase of the ovulatory cycle is characterized
by elevated serum progesterone levels and also highly
variable serum levels of estrogens, especially 17 b estradiol.
We confirmed ovulatory cycle phases by determination of
serum progesterone concentrations, which have been re-
ported as the most direct and accurate confirmation of
luteinization [30]. We did not observe significant changes in
mean arterial pressure and body weight from mid-follicular
to mid-luteal phases of the ovulatory cycle. Our findings are
in agreement with several previous reports indicating the
absence of cyclicity in these variables [31, 32]. We esti-
mated renal function during the ovulatory cycle using the
Cockcroft-Gault algorithm [18] and did not observe signif-
icant changes in estimates of glomerular filtration rate
(GFR) during the ovulatory cycle. Previous studies have
not reported consistently on the cyclicity of GFR during the
ovulatory cycle, with some studies reporting a rise in GFR
during the luteal phase [31, 33] and other investigators
demonstrating a lack of cyclicity [34].
Results from enzyme-kinetic studies performed on a
subgroup of white and black subjects revealed no differ-
ences in Km values for urinary kallikrein activity, but
significant differences in Vmax values between white and
black subjects. This suggests that the decreased kallikrein
activity in black subjects was quantitative, and not to due
alterations in substrate binding (qualitatively defective kal-
likrein enzyme).
Results from mixing studies performed on a subgroup of
white and black subjects demonstrated that there was no
difference in kallikrein activity in mixed urine samples from
white and black subjects compared to the enzymatic activity
of the same samples assayed separately. This suggests that
the diminished kallikrein activity in black subjects was not
due to the presence of a kallikrein inhibitor [35, 36].
Several environmental factors including dietary potas-
sium may influence urinary kallikrein excretion [37]. In-
creased dietary potassium causes increased aldosterone
release that may mediate an increase in urinary kallikrein
excretion [28]. Consistent with previous studies demon-
strating racial differences in potassium excretion [38],
which in turn have been attributed to racial differences in
dietary potassium intake [38], white subjects in our study
had significantly higher urinary potassium excretion rates
than black subjects (Table 1). However, after controlling
for the effects of potassium excretion, the observed racial
differences in urinary kallikrein excretion were still highly
significant (P 5 0.003; Table 3). Analysis of co-variance
(ANCOVA), in which only urinary potassium and race
were entered as covariates, also demonstrated that after
controlling for racial differences in urinary potassium ex-
cretion, the effect of race on urinary kallikrein excretion
was still highly significant (P 5 0.001)
Renal kallikrein excretion may be modulated by miner-
alocorticoids, especially aldosterone [28]. In this study
urinary aldosterone concentrations increased significantly
from mid-follicular to mid-luteal phases to a comparable
degree in both white and black groups. Thus, despite
cyclical changes in urinary aldosterone excretion during the
menstrual cycle in black females, there were no changes in
urinary kallikrein excretion.
It has been postulated that variation in urinary kallikrein
excretion during the ovulatory cycle could be related to
ovarian hormones and mineralocorticoid activity [14]. In-
deed, the promoter region of the renal kallikrein (KLK1)
gene has several steroid response elements [39] such that
ovulatory cycle changes in renal kallikrein excretion may
reflect cyclic increases in kallikrein synthesis mediated at
the level of transcription. We assessed correlations by
linear least-squares regression analysis (data not shown)
between changes in urinary kallikrein excretion during the
Fig. 3. Double reciprocal (Lineweaver-Burk)
plot of enzyme reaction velocity (y axis 5 1/V,
L/U) versus substrate concentration (1/S 2266,
1/mM) for renal kallikrein, in representative
white (V) and black (v) subjects. Vmax,
enzymatic activity (U/liter) at optimal or
saturating substrate concentration [S]; Km,
substrate concentration for half-maximal
enzymatic activity. Km values did not differ
between white and black subjects. Table insert
shows grouped data for white (N 5 7) and
black (N 5 7) subjects. White and black groups
had significantly different Vmax for renal
kallikrein (P , 0.05) but no differences in Km
values were observed (P 5 0.840).
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menstrual cycle and changes in serum progesterone, serum
estrogens, plasma renin activity and urinary aldosterone
concentrations. Whereas no significant correlations were
noted between urinary kallikrein and ovarian hormones
(both progesterone and estrogens), there was a trend
towards a weak correlation between urinary kallikrein and
urinary aldosterone concentrations (r 5 0.358, P 5 0.079,
N 5 26). No significant correlations were observed between
urinary kallikrein and plasma renin activity.
The human kallikrein gene family is composed of three
members, all structurally located as a gene cluster on
chromosome 19q13.3-13.4: tissue (renal) kallikrein
(KLK1); prostate-specific antigen (PA or APS); and glan-
dular kallikrein (KLK2 or hGK-1) [40, 41]. In addition, the
plasma kallikrein gene (KLK3) has been localized to
chromosome 4q34-35 [42]. Renal kallikrein enters the urine
at the distal tubule and urinary kallikrein is thought to
reflect the levels of renal kallikrein [1, 43, 44]. Recently,
Song, Chao and Chao, using polymerase chain reaction
(PCR) allele-specific amplification and DNA sequencing,
identified DNA polymorphisms (length and nucleotide
sequence variations) in the 59-flanking (promoter) region
of the human tissue (renal) kallikrein (KLK1) gene on
chromosome 19q13.3-13.4 [39]. Among the different alleles
in this polymorphic region, some genotypes occurred only
in African-Americans [39]. In addition, in vitro transfection
promoter/reporter studies revealed that specific polymor-
phisms in this hypervariable region many be associated with
marked alterations in kallikrein gene promoter activity [39].
These results suggest that alterations in kallikrein expres-
sion may be intrinsic to variations within the kallikrein
gene.
Results from several recent studies suggest that low
urinary kallikrein activity may cluster with a variety of other
clinical predictors of hypertension. The renal kallikrein/
kinin system may have a major influence on renal sodium
homeostasis, with potent natriuretic effects at distal
nephron sites [45]. Recent studies have demonstrated that
diminished urinary kallikrein excretion is associated with
salt sensitivity of blood pressure [9–11]. Salt-sensitivity, in
turn, tends to cluster with a variety of other traits associated
with hypertension and increased cardiovascular risk, such
as microalbuminuria, elevated sodium-lithium counter-
transport, insulin resistance, and dyslipidemia [27, 46–52].
Thus, these observations may have important implications
for hypertension in African-Americans, in particular, since
the constellation of low renal kallikrein, salt sensitivity,
insulin resistance, and microalbuminuria may be especially
prevalent in this ethnic group [27, 46–52].
Our results suggest profound blunting of ovulatory cycle
changes in urinary kallikrein activity in black females.
Additionally, enzyme kinetic studies revealed that these
racial differences in renal kallikrein excretion appear to be
quantitative, rather than due to qualitative differences in
the renal kallikrein enzyme. Taken together, these results
are consistent with dysregulation of kallikrein biosynthetic
responses in African-Americans women, a group at in-
creased risk of essential hypertension.
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